Asthma and pregnancy

INTRODUCTION

Asthma during pregnancy is a significant public health issue because it is one of the most potentially serious medical problems to complicate pregnancy. Studies have shown that having asthma during pregnancy puts both mother and baby at risk for complications¹.

Several studies indicate that pregnancies in patients with asthma are associated with an increased risk for adverse obstetric outcomes, such as preeclampsia, gestational diabetes mellitus, cesarean section rate, preterm birth (PB), low birth weight (LBW), and intrauterine growth restriction².

Different prevalence rates of asthma during pregnancy are described. In Canada, asthma affects only 0.43% of pregnant women, while this rate can reach 8.4% in the United States. In Brazil, although there are not many studies on the subject, it is estimated that the prevalence of asthma in this population is closer to American standards, ranging from 5 to 8%³.

An observational study using secondary data from a birth cohort study in the metropolitan area of Aracaju applied a questionnaire to 4,757 women and identified that 299 had a diagnosis of asthma before or during pregnancy, corresponding to a prevalence of 6.3%⁴.

ASTHMA DIAGNOSIS IN PREGNANT WOMEN

Asthma is characterized by respiratory symptoms such as shortness of breath, wheezing, cough, and chest tightness that are often worse at night and may vary over time and intensity, together with variable airflow obstruction. Symptoms can be triggered by viral infections, exposure to allergens, smoke, exercise, changes in weather, and irritants. Detailed anamnesis and physical examination support asthma diagnosis. Additionally, documented expiratory airflow limitation and excessive variability in lung function corroborate the diagnosis⁵.

Symptoms of asthma are similar in pregnant and nonpregnant patients. However, if a pregnant woman complains of shortness of breath or chest tightness, the asthma diagnosis should be carefully made based only on her symptoms⁶. Frequently, pregnant women complain of shortness of breath or chest tightness (approximately two-thirds) during the pregnancy period⁷.

During pregnancy, several physiological and structural changes can contribute to a sensation of dyspnea, such as the dilated uterus, elevated diaphragm, and increased anteroposterior and transverse diameter of the thorax. Such changes are compensated by a reduction of thoracic compliance, and as a result, the functional residual capacity (FRC) and total lung function (TLC) decrease by 20 and 5%, respectively⁸.

Spirometry parameters such as forced expiratory volume in first second (FEV1), forced vital capacity (FVC), and FEV1/FVC do not change during pregnancy compared to reference values in the nonpregnancy period. Spirometry may help asthma diagnosis in pregnant women by detecting reversible airway obstruction and helping monitor response to treatment. Bronchial provocation tests are not advisable to be carried out in pregnant women to prevent maternal hypoxia and fetal distress.

Phenotyping asthma allows optimizing disease management and treatment choice, as well as identifying pharmacological pathways that are more likely to respond positively to treatment. In asthmatic pregnant women, identifying the primary phenotype as allergic or non-allergic may be enough. Serological tests for allergen-specific immunoglobulin E (IgE) are preferred to skin and provocation tests, which should be postponed until after birth because of possible, though rare, anaphylactic reactions⁹. During the pregnancy period, Th2 upregulation and other immunity changes may lead to bronchial asthma exacerbation.

PREGNANCY EFFECTS ON ASTHMA

Data about the specific mechanisms by which pregnancy might affect asthma symptoms and control are still weak. Despite that, it is known that pregnancy can cause worsening of asthma in around 30–40% of women⁵,¹⁰.

The worsening of asthma, with more frequent exacerbations and poor symptom control that occurs in some pregnancies, is thought to be caused by different factors, including mechanical or hormonal changes⁵. Pregnancy might also increase the susceptibility to viral respiratory infections¹¹. On the contrary, sometimes, it might be challenging to differentiate the real worsening of asthma from pregnancy-induced dyspnea. The lung function evaluation, especially FEV1, not substantially affected during pregnancy, along with other associated asthma symptoms, might be a clue for making the difference between these situations¹².

EFFECTS OF ASTHMA ON PREGNANCY

The impact of asthma during pregnancy on maternal, fetal, neonatal, and childhood outcomes has been already demonstrated in several studies. Some data suggest that asthma severity and the intensity of treatment, rather than control or exacerbations, may be related to the increased risk of preeclampsia in asthmatic women¹²,¹³.

Other studies indicate that pregnant women with asthma, in addition to preeclampsia, are at significantly increased risk of outcomes including emergency cesarean section, LBW and PB, and neonatal intensive care unit (NICU) admissions¹³.

Uncontrolled asthma can lead to hypoxia and other physiological abnormalities that could decrease fetal blood oxygen and result in abnormal growth and development of the fetus. Acute asthma exacerbations or a recurrent loss of asthma control during pregnancy have been identified as the most significant events to affect fetal morbidity and mortality than inhaled corticosteroids (ICS) use¹³,¹⁴.

A significantly increased risk of LBW infants was noted in subjects experiencing asthma exacerbation during pregnancy (RR 3.02) and using oral corticosteroids (OC) (RR 1.41) ¹². On the contrary, controlled asthma during pregnancy appears to protect the fetus from adverse outcomes¹³,¹⁵,¹⁶.

ASTHMA SEVERITY AND CONTROL

Asthma control assessment should be part of the anamnesis of all pregnant women diagnosed with asthma. Asthma control can be assessed using simple and easy-to-apply questionnaires, the main ones being Global Initiative for Asthma (GINA), Asthma Control Questionnaire (ACQ-7), and Asthma Control Test (ACT) (Table 1)⁵,¹⁷.

Table 1
Definition of asthma control by different instruments.

Instrument/items		Controlled asthma	Partially controled asthma	Uncontrolled asthma
GINA
	Daytime asthma symptoms more than twice/week?	None	1–2 items	3–4 items
	Any night waking due to asthma?
	SABA reliever for symptoms more than twice/week?
	Any activity limitation due to asthma?
ACQ-7
	Number of nocturnal awakenings	≤0.75	0.75 to <1.5	>1.5
	Intensity of symptons
	Limitation of activities due to asthma
	Intensity of dyspnea
	Wheezing (how long)
	Rescue medication
	Pre-bronchodilator FEV1
ACT
	Limitation of activities due to asthma	≥20	15–19	≤15
	Dyspnea
	Nocturnal awakenings due to asthma
	Rescue medication
	Self-assessment of asthma control

• GINA: Global Initiative for Asthma; ACQ-7: 7-item Asthma Control Questionnaire – 0-7 points per item; ACT: asthma control test – 0-5 points per item. The ACQ can be used without spirometry; in this case, it is referred to as ACQ-6. If used without spirometry or rescue medication, it is referred to as ACQ-5. Reference: Pizzichini et al.¹⁷.

Medication adherence and inhalation technique should always be evaluated¹⁷. In 2005, data from Australian pregnant women with asthma demonstrated that in their initial visit with an asthma nurse educator at 20 weeks of pregnancy, women with asthma had poor adherence, with 40% self-reported nonadherence with ICS, insufficient knowledge about asthma medications (42% were inadequate), and poor device technique (16% had inadequate inhaler technique)¹⁸.

In addition, common comorbidities such as rhinitis, gastro-esophageal reflux, overweight/obesity, and smoking which can contribute to worsening asthma, should be identified and managed¹⁷,¹⁹.

ASTHMA TRIGGERS AND COMORBIDITIES DURING PREGNANCY

Avoiding exacerbation triggers and proper comorbidities management are critical elements of successful asthma management and control.

Pregnant patients’ frequency and severity of respiratory viral infections are higher for those with asthma⁷. Among all pregnant women, influenza is associated with increased morbidity and mortality, especially in the second trimester⁷. During the H1N1 pandemic season, asthma was the most common comorbidity in 23% of cases reported in pregnant women who developed influenza A infection, and 44% of pregnant women who died of H1N1 influenza had asthma⁷.

Other triggers are environmental (e.g., dust and pollutants) and occupational exposure. Aspirin, other nonsteroidal anti-inflammatory drugs, and beta-blockers (in oral or ophthalmic formulations) may cause bronchospasm¹⁷.

Pregnancy is a moment of unique psychological variability due to neuroendocrinal changes, excessive maternal weight gain, and additional stress regarding fetus safety¹². Predictably, anxiety and depression potentially impact patient-related outcomes in 6–15% of pregnant asthmatics, including an increased risk of unplanned caesarian delivery and poor asthma control²⁰.

Obesity and gastroesophageal reflux are prevalent comorbidities in pregnant asthmatics. Maternal obesity during pregnancy represents a unique phenotype and endotype associated with increased airway obstruction, ICS resistance, upregulation of inflammatory pathways, frequent exacerbations, and increased incidence of asthma in children²¹. Exercise and combined dietary interventions significantly improve asthma control and avoid excessive maternal weight gain throughout pregnancy.

GESTATIONAL COMPLICATIONS IN PREGNANT WOMEN WITH ASTHMA

Asthma is strongly associated with preeclampsia, placental abruption, placenta previa, and obstetric hemorrhage. Decades of research have linked asthma to increased rates of cesarean delivery⁷. In addition to obstetric complications, asthma is associated with multiple comorbid maternal conditions⁷. Pediatric complications associated with poorly controlled maternal asthma include LBW and small for gestational age (SGA), with the risk of LBW increasing with asthma severity⁷,¹⁶. Table 2 shows the main gestational complications in pregnant women with asthma and fetus⁷.

Table 2
Main gestational complications in pregnant women with asthma.

Maternal and obstetric complication	Fetal complications
Miscarriage	Low weight at birth
Gestational diabetes	Restricted intrauterine growth
Premature birth	Congenital malformations
Preeclampsia	Increase in perinatal mortality
Gestational hypertension	Fetal anomalies
Pre and pos partum hemorrhage
Cesarian delivery
Pulmonary embolism
Premature rupture of membrane

• Reference: Bonham et al.⁷.

TAILORED ASTHMA TREATMENT IN THE PREGNANCY

Asthma education is critical to building partnership care during pregnancy. The obstetric population often needs better asthma self-management skills and knowledge, regardless of disease severity¹⁸. Parents should be aware that poor asthma control in pregnancy increases the risk of maternal complications and poor neonatal outcomes¹³,²².

Active self-management education plays a key role in obstetric care by improving treatment adherence, asthma control, and inhaler technique and developing a written plan for unstable asthma.

Maternal smoking during pregnancy significantly increases the risk of suboptimal fetal growth and PB, enhances the risk of asthma exacerbations, impairs the effectiveness of ICS, and increases mortality²³,²⁴. Smoking cessation programs should ideally involve a multidisciplinary approach with periodic brief counseling interventions and cognitive behavioral therapy. Data about the safety of pharmacological approaches to smoking cessation in pregnancy are limited²⁵.

PHARMACOLOGICAL TREATMENT

Pharmacological treatment in asthmatics during pregnancy aims to achieve asthma control and prevent future risks, such as exacerbations, accelerated lung function decline, and adverse effects of treatment¹⁷. Although drug safety for pregnant women and the fetus is a general concern during pregnancy, the use of ICS, short-acting B2-agonists (SABA), short-acting anticholinergic (SAMA), long-acting B2-agonist bronchodilators (LABA), montelukast, and theophylline is not associated with a significant increase in fetal abnormalities⁵,²⁶.

As bronchial inflammation is a critical pathogenic mechanism in asthma, the use of ICS is the mainstay of pharmacological asthma treatment, as monotherapy or in association with LABA¹⁷. According to GINA, ICS withdrawal is not recommended during pregnancy⁵.

Even though LABA monotherapy should be avoided due to increased asthma-related mortality, the combined therapy of ICS/LABA is the preferred option as an add-on therapy for patients who failed to achieve control with low/moderate doses of ICS. There was a recent paradigm shift in the management of mild asthma with the recommendation of a fixed-dose ICS/formoterol as maintenance and reliever therapy⁵.

Add-on therapy with tiotropium provides functional gain and reduces exacerbations in uncontrolled asthmatics under moderate-high doses of ICS/LABA⁵,¹⁷. The small number of pregnant women with asthma in randomized clinical trials difficult to conclude on the efficacy and safety of long-acting muscarinic antagonist (LAMA) in this population.

Leukotriene receptor antagonists (LTRA) are recommended as an add-on medication to other maintenance therapies in pregnant women⁵.

As in the general population, severe asthma in pregnancy is defined by persistent symptoms and/or exacerbations despite proper inhaler technique and good treatment adherence in patients treated with a medium-high dosage of ICS combined with other classes of asthma maintenance therapy⁵,²⁷. Although a study has suggested a relationship between a high dose of ICS and fetal malformations, this should be explained by asthma severity based on the relationships between exacerbations and congenital malformations demonstrated by the same group²⁸.

Some patients with severe asthma may require regular OC use to achieve adequate asthma control. OC use has been associated with an increased risk of PB and LBW infants in exposed women. An increased risk of orofacial clefts was reported in a meta-analysis of case-control studies, but this increased risk was not confirmed in a large cohort study¹⁵.

Recently, biological agents have been used in patients with severe refractory eosinophilic allergic or non-allergic asthma, but data on the use of these biologics in pregnancy are sparse²,²⁹. Omalizumab (anti-IgE therapy) is one of the options for moderate-severe allergic asthma. It is currently the only asthma biological with limited available human safety data from the EXPECT pregnancy registry that reported no increased risk of congenital anomalies, stillbirths, premature birth, and SGA³⁰.

EXACERBATION MANAGEMENT

Studies showed that nearly half of the pregnant asthmatic women experience exacerbations, and one-fourth will experience severe exacerbations, necessitating emergency department (ED) visits or hospitalizations²⁹,³¹.

Early and aggressive interventions are necessary to treat severe acute asthma exacerbations in pregnant women to minimize maternal and fetal hypoxia risk³².

A short story and focused physical examination should be performed rapidly with particular attention to vital signs, maternal oxygen saturation, lung function, and the work of breathing, as outlined in Table 3⁵. If feasible, fetal monitoring should be performed to evaluate fetal distress⁵,³³.

Table 3
Initial severity assessment of acute asthma in pregnancy.

Findings	Mild/moderate	Severe
Speaking in	Sentences or phrases	Words or unresponsive
Respiratory rate	18–19/min	>30/min
Heart rate	100–120 beats/min	>120 beats/min
Peak flow/FEV1 (%predicted)	50–75%	<50%
Pulse oximetry (room air)	90–95%	<90%

• Reference: GINA⁵.

Recommended primary pharmacological treatment is similar for both pregnant and general adult populations and includes immediate use of inhaled ß2-agonists, inhaled ipratropium, and timely (within 30–60 min) administration of systemic corticosteroids (prednisone 60 mg orally daily up to 5 days) or 2 mg/kg methylprednisolone IV in the ED. Oxygen supplementation is recommended in hypoxemic patients to maintain arterial oxygen saturation between 94 and 98%²⁹.

Status asthmaticus gravidus is a life-threatening asthma syndrome that may require additional therapy (i.e., magnesium sulfate and Heliox), most of which have limited efficacy data in pregnant patients. Intubation and mechanical ventilation are indicated in patients with refractory respiratory failure²⁹.

SAFETY OF ASTHMA MEDICATIONS DURING PREGNANCY

Despite the lack of evidence for the adverse effects of asthma treatment in pregnancy, many women and doctors remain concerned⁵. Some published data summarize the evidence for human pregnancy safety data for asthma medications¹²,²⁶,³⁴,³⁵. There is evidence for ICS safety during pregnancy (Evidence A) ^26,36. Budesonide is considered the first-line IC to initiate therapy because it is the most IC studied in pregnancy and shows no increased risk of congenital anomalies or stillbirths. However, another IC may be continued if asthma is controlled¹²,²⁶.

SABAs are recommended as safe in pregnancy, with salbutamol being the most studied as a rescue medication. There is evidence for LABA safety during pregnancy (Evidence A)²⁶,³⁶, although LABAs are only recommended in fixed-dose combination with ICSs to moderate-severe asthma. There is no preference among available LABAs (i.e., formoterol or salmeterol). No data are available for using ultra LABAs (i.e., indacaterol and vilanterol) during pregnancy²⁶.

The risk of congenital anomalies of ICS/LABA combination versus high-dose ICS alone in the first trimester was similar in moderate-severe asthma, suggesting safety in pregnancy³⁷. On the contrary, there is limited data on ICS/formoterol combination safety as a maintenance and reliever therapy²⁶.

SAMA associated with SABA has been recommended for managing severe asthma exacerbation not responding to SABA monotherapy. No well-controlled studies of tiotropium [LAMA] have been performed in pregnant women¹²,²⁶.

The Observational Study of the Use and Safety of Xolair (omalizumab) during Pregnancy Trial (EXPERT)³⁰ showed similar rates of major congenital anomalies in both groups (omalizumab vs. control). Therefore, treatment may be continued during pregnancy if the benefits outweigh the risks; however, it is not currently recommended to start omalizumab in pregnant women²⁶,³⁰.

There are no available prospective data regarding the safety of other monoclonal antibodies (i.e., mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab) for severe asthma during pregnancy. Animal studies found no teratogenic effects. Pregnancy registries https://mothertobaby.org/ongoing-study/nucalamepolizumab/, https://mothertobaby.org/ongoingstudy/fasenra/, and https://mothertobaby.org/ongoing-study/dupixent/ are ongoing for all of them, except for tezepelumab²⁶,³⁸.

For the patient who requires OC for asthma control, its benefit in preventing severe exacerbations outweighs the potential risk of congenital abnormalities²⁶,³⁴,³⁵.

MANAGEMENT DURING LABOR AND DELIVERY

There are no published studies specifically addressing intrapartum management in women with respiratory disease and whether there are any clinical benefits of cesarean section versus vaginal birth³⁵. Although there is a higher planned cesarean rate among moderate-severe asthmatics compared with mild asthma patients, labor induction is rarely indicated due to asthma²²,³⁹.

Controller asthma medications should be maintained, as well as a reliever, if needed, during labor and delivery⁵,³⁵. Asthma exacerbations are uncommon; however, bronchoconstriction may be induced by hyperventilation during labor and should be managed with SABA⁵. In asthmatics receiving OC, there is a potential risk of maternal hypothalamic-pituitary-adrenal axis suppression and a dose of hydrocortisone intravenously during active labor, or cesarean section should be used³⁵,⁴⁰.

Pre-delivery evaluation and multidisciplinary planning are the cornerstones in managing women with respiratory disease³⁵, decreasing severe respiratory complications⁴¹, probably to close collaboration between obstetricians and respiratory physicians regarding pregnant asthmatic women²².

Some obstetric considerations must be made. The use of prostaglandin E2 for labor induction or oxytocin (second and third labor stages) has not been associated with worsening lung function or asthma exacerbation³⁵. Nevertheless, ergotamine may cause bronchospasm, particularly in association with general anesthesia. Oxytocin is the uterotonic choice for the active third stage of labor³⁵,⁴⁰. Epidural anesthesia is preferred during delivery because it reduces oxygen consumption and minute ventilation. In an emergency cesarean section, this can be extended into proper anesthesia, avoiding the need for airway management. Ketamine and halogenated anesthetics, with a bronchodilator effect, are preferred if general anesthesia is necessary⁴⁰.

Post-partum hemorrhage may be increased in women with asthma³⁵. Medications used for its management may affect the respiratory system reinforcing the need for collaboration between the obstetric and respiratory teams to optimize management³⁵.

CONCLUSION

Asthma during pregnancy is a significant public health issue. Studies have shown that having asthma during pregnancy puts both mother and baby at risk for complications. Although there is concern about the use of asthma medications during pregnancy, disease control and exacerbations prevention outweigh the potential risk. Close collaboration between obstetricians and respiratory physicians is essential to improve clinical outcomes in asthmatic women during pregnancy.

• Funding: none.
• Brazilian Society of Pulmonology / Phthisiology

REFERENCES

• ¹ Xu Z, Doust JA, Wilson LF, Dobson AJ, Dharmage SC, Mishra GD. Asthma severity and impact on perinatal outcomes: an updated systematic review and meta-analysis. BJOG. 2022;129:367-77.
• ² Namazy JA, Schatz M. Contemporary management and treatment strategies for asthma during pregnancy. Expert Review of Respiratory Medicine. 2021;15(9):1149-57.
• ³ Mendes RFP, Nomura RMY, Ortigosa C, Francisco RPV, Zugaib M. Asma na gestação: efeitos na vitalidade fetal, complicações maternas e perinatais. Revista da Associação Médica Brasileira [online]. 2013, v. 59, n. 2[Acessado 10 dezembro 2022], pp. 113-9. Available from: https://doi.org/10.1016/j.ramb.2012.08.001
  » https://doi.org/10.1016/j.ramb.2012.08.001
• ⁴ Almeida ML, Santana PA, Guimarães AM, Gurgel RQ, Vianna EO. Asma e gravidez: repercussões no recém-nascido. J Bras Pneumol. 2010;36(3):293-300.
• ⁵ Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2022. [cited on Dec 9, 2022] Available from www.ginasthma.org
  » www.ginasthma.org
• ⁶ Weinberg, J. Diagnosis of asthma during pregnancy. J Clin Res. 2022(6):152.
• ⁷ Bonham CA, Patterson KC, Strek ME. Asthma outcomes and management during pregnancy. Chest. 2018;153(2):515-27.
• ⁸ Mehta N, Kenneth Chen, Hardy E, Powrie R. Respiratory disease in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2015;29(5):598-611.
• ⁹ Pali-Schöll I, Namazy J, Jensen-Jarolim E. Allergic diseases and asthma in pregnancy, a secondary publication. World Allergy Organ J. 2017;10(1):10. https://doi.org/10.1186/s40413-017-0141-8
  » https://doi.org/10.1186/s40413-017-0141-8
• ¹⁰ Williamson G, O'Connor A, Kayleigh E. Women's experiences of personalized support for asthma care during pregnancy: a systematic review of the literature. BMC Pregnancy Childbirth. 2017;17:69.
• ¹¹ Forbes RL, Gibson PG, Murphy VE, Wark PAB. Impaired type I and III interferon response to rhinovirus infection during pregnancy and asthma. Thorax. 2012;67(3):209-14.
• ¹² Namazy JA, Schatz M. Chronic management of asthma during pregnancy. Immunology and Allergy Clinics. 20231;43(1):65-85.
• ¹³ Meakin AS, Saif Z, Seedat N, Clifton VL. The impact of maternal asthma during pregnancy on fetal growth and development: a review. Expert Review of Respiratory Medicine. 2020;14(12):1207-16.
• ¹⁴ Murphy VE, Gibson P, Talbot PI, Clifton VL. Severe asthma exacerbations during pregnancy. Obstet Gynecol. 2005;106(5 Pt 1):1046-54.
• ¹⁵ Namazy JA, Murphy VE, Powell H, Gibson PG, Chambers C, Schatz M. Effects of asthma severity, exacerbations, and oral corticosteroids on perinatal outcomes. Eur Respir J. 2013;41(5):1082-90.
• ¹⁶ Murphy V, Namazy J, Powell H, Schatz M, Chambers C, Attia J, et al. A meta-analysis of adverse perinatal outcomes in women with asthma. BJOG 2011;118:1314-23.
• ¹⁷ Pizzichini MMM, Carvalho-Pinto RM, Cançado JED, Rubin AS, Neto AC, Cardoso AP, et al . Brazilian thoracic association recommendations for the management of asthma. J Bras Pneumol. 2020;46(1):e20190307.
• ¹⁸ Murphy VE, Gibson PG, Talbot PI, Kessell CG, Clifton VL. Asthma self-management skills and the use of asthma education during pregnancy. Eur Respir J. 2005;26(3):435-41.
• ¹⁹ Murphy VE. Managing asthma in pregnancy. Breathe. 2015;11:258-67.
• ²⁰ Rejnö G, Lundholm C, Öberg S, Lichtenstein P, Larsson H, D'Onofrio B, et al. Maternal anxiety, depression and asthma and adverse pregnancy outcomes - a population based study. Sci Rep. 2019;9(1):13101.
• ²¹ Miethe S, Karsonova A, Karaulov A, Renz H. Obesity and asthma. J Allergy Clin Immunol. 2020;146(4):685-93.
• ²² Gade EJ, Tidemandsen C, Hansen AV, Ulrik CS, Backer V. Challenges in the successful management of asthma during conception, pregnancy and delivery. Breathe [Internet]. 2022 Jun 1 [cited Dec 24, 2022];18(2). Available from: https://breathe.ersjournals.com/content/18/2/220013
  » https://breathe.ersjournals.com/content/18/2/220013
• ²³ Zheng X, Guan W, Zheng J, Ye P, Liu S, Zhou J, et al. Smoking influences response to inhaled corticosteroids in patients with asthma: a meta-analysis. Current Medical Research and Opinion. 20121;28(11):1791-8.
• ²⁴ Hodyl NA, Stark MJ, Scheil W, Grzeskowiak LE, Clifton VL. Perinatal outcomes following maternal asthma and cigarette smoking during pregnancy. European Respiratory Journal. 2014;43(3):704-16.
• ²⁵ Tran DT, Preen DB, Einarsdottir K, Kemp-Casey A, Randall D, Jorm LR, et al. Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: a population-based cohort study. BMC Medicine. 2020;18(1):15.
• ²⁶ Cusack RP, Whetstone CE, Gauvreau GM. Use of asthma medication during gestation and risk of specific congenital anomalies. Immunol Allergy Clin North Am. 2023;43(1):169-85.
• ²⁷ Carvalho-Pinto RM, Cançado JED, Pizzichini MMM, Fiterman J, Rubin AS, Cerci Neto A, et al. 2021 Brazilian thoracic association recommendations for the management of severe asthma. J Bras Pneumol. 2021;47(6):e20210273.
• ²⁸ Breton M, Beauchesne MF, Lemiere C, Rey E, Forget A, Blais L. Risk of perinatal mortality associated with asthma during pregnancy: 2-stage sampling cohort study. Ann Allergy Asthma Immunol. 2010;105(3):211-7.
• ²⁹ Cairns CB, Kraft M. Status asthmaticus gravidus: emergency and critical care management of acute severe asthma during pregnancy. Immunol Allergy Clin N Am. 2023;43(1):87-102.
• ³⁰ Namazy JA, Blais L, Andrews EB, Scheuerle AE, Cabana MD, Thorp JM, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol 2020;145(2):528-36, e521.
• ³¹ Labor S, Dalbello Tir AM, Plavec D, Juric I, Roglic M, Vukelic JP, et al. What is safe enough - asthma in pregnancy - a review of current literature and recommendations. Asthma Res Pract. 2018;4:1.
• ³² Grzeskowiak LE, Smith B, Roy A, Dekker GA, Clifton VL. Patterns, predictors and outcomes of asthma control and exacerbations during pregnancy: a prospective cohort study. ERJ Open Res. 2016;2(1):00054-2015.
• ³³ Cydulka RK. Acute asthma during pregnancy. Immunol Allergy Clin N Am 2006;26(1):103-17.
• ³⁴ Chamber CD, Krishnan JA, Alba L, Albano JD, Bryant AS, Carver M, et al. The safety of asthma medications during pregnancy and lactation: clinical management and research priorities. J Allergy Clin Immunol. 2021;147(6):2009-20.
• ³⁵ Middleton PG, Gade EJ, Aguilera C, MacKillop L, Button BM, Coleman C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020;55:1901208.
• ³⁶ Lim A, Stewart K, König K, George J. Systematic review of the safety of regular preventive asthma medications during pregnancy. Ann Pharmacother. 2011;45(7-8):931-45.
• ³⁷ Eltonsy S, Forget A, Beauchesne M-F, Blais L. Risk of congenital malformations for asthmatic pregnant women using a long-acting b2-agonist and inhaled corticosteroid combination versus higher-dose inhaled corticosteroid monotherapy. J Allergy Clin Immunol 2015;135(1):123-30. e122.
• ³⁸ Ramos C.L, Namazy J. Monoclonal antibodies (biologics) for allergic rhinitis, asthma, and atopic dermatitis during pregnancy and lactation. Immunol Allergy Clin North Am. 2023;43(1):187-97.
• ³⁹ Tinker SC, Broussard CS, Frey MT, Gilboa SM. Prevalence of prescription medication use among non-pregnant women of childbearing age and pregnant women in the United States: NHANES, 1999–2006. Matern Child Health J. 2015;19:1097-106.
• ⁴⁰ Vieira AC, Pité H, Morais-Almeida M. Asthma and pregnancy in the 2020 decade: still a matter of concern. J Matern Fetal Neonatal Med. 2022;35(25):6498-504.
• ⁴¹ Murphy VE, Clifton VL, Gibson PG. Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes. Thorax. 2006;61:169-76.

Publication Dates

• Publication in this collection
  04 Aug 2023
• Date of issue
  2023

History

• Received
  13 Jan 2023
• Accepted
  17 Mar 2023